Medicine guide

Phendimetrazine Tartrate

35 mg · Tablet

Prescription only
Controlled substance · CIII
Sympathomimetic Amine Anorectic

Active substance: Phendimetrazine Tartrate
Made by: Calvin Scott & Co., Inc.
Source: Official label

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2026-05-21

What it is

Sympathomimetic Amine Anorectic

Used for

Phendimetrazine tartrate is indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body…

The label’s usual adult dose

1 tablet (35 mg) twice a day or three times a day one hour before meals.

Dosage should not exceed 2 tablets three times a day.

Full directions ↓

Do not take it if

Known hypersensitivity or idiosyncratic reactions to sympathomimetics.

All warnings ↓

Good to know

Prescription only
Controlled substance (schedule III) — extra rules apply to prescribing and refills
FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02

11other products contain Phendimetrazine Tartrate — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

Phendimetrazine tartrate is indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m 2 or higher who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone.
Below is a chart of Body Mass Index (BMI) based on various heights and weights.
BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared.
Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.
Phendimetrazine tartrate is indicated for use as monotherapy only. bmi index

From the official label · 2026-05-21 · DailyMed

How it works

From this product’s own US prescribing label.

Phendimetrazine tartrate is a sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines.
Actions include central nervous system stimulation and elevation of blood pressure.

Half-life3.7 h

Mostly cleared after≈ 18.5 hfive half-lives — our arithmetic

How the body breaks it down

Some of the drug is metabolized to phendimetrazine and phendimetrazine-N-oxide.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-05-21

Do not take it if

Known hypersensitivity or idiosyncratic reactions to sympathomimetics.
Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate and severe hypertension, hyperthyroidism, and glaucoma.
Highly nervous or agitated patients.
Patients with a history of drug abuse.
Patients taking other CNS stimulants, including monoamine oxidase inhibitors.

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

Usual Adult Dosage:
1 tablet (35 mg) twice a day or three times a day one hour before meals.
Dosage should be individualized to obtain an adequate response with the lowest effective dosage.
In some cases, ½ tablet (17.5 mg) per dose may be adequate.
Dosage should not exceed 2 tablets three times a day.

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Phendimetrazine tartrate should not be used in combination with other anorectic agents, including prescribed drugs, over-the-counter preparations and herbal products.
In a case-control epidemiological study, the use of anorectic agents, including phendimetrazine tartrate, was associated with an increased risk of developing pulmonary hypertension, a rare, but often fatal disorder.
The use of anorectic agents for longer than three months was associated with a 23-fold increase in the risk of developing pulmonary hypertension.
Increased risk of pulmonary hypertension with repeated courses of therapy cannot be excluded.
The onset or aggravation of exertional dyspnea, or unexplained symptoms of angina pectoris, syncope, or lower extremity edema suggest the possibility of occurrence of pulmonary hypertension.
Under these circumstances, phendimetrazine tartrate should be immediately discontinued, and the patient should be evaluated for the possible presence of pulmonary hypertension.
Valvular heart disease associated with the use of some anorectic agents such as fenfluramine and dexfenfluramine has been reported.
Possible contributing factors include use for extended periods of time, higher than recommended dose, and/or use in combination with other anorectic drugs.
However, no cases of this valvulopathy have been reported when phendimetrazine tartrate has been used alone.
The potential risk of possible serious adverse effects such as valvular heart disease and pulmonary hypertension should be assessed carefully against the potential benefit of weight loss.
Baseline cardiac evaluation should be considered to detect pre-existing valvular heart diseases or pulmonary hypertension prior to initiation of phendimetrazine treatment.
Phendimetrazine tartrate is not recommended in patients with known heart murmur or valvular heart disease.
Echocardiogram during and after treatment could be useful for detecting any valvular disorders which may occur.
To limit unwarranted exposure and risks, treatment with phendimetrazine tartrate should be continued only if the patient has satisfactory weight loss within the first 4 weeks of treatment (i.e., weight loss of at least 4 pounds, or as determined by the physician and patient).
Tolerance to the anorectic effect of phendimetrazine develops within a few weeks.
When this occurs, its use should be discontinued; the maximum recommended dose should not be exceeded.
Use of phendimetrazine tartrate within 14 days following the administration of monoamine oxidase inhibitors may result in a hypertensive crisis.
Abrupt cessation of administration following prolonged high dosage results in extreme fatigue and depression.
Because of the effect on the central nervous system, phendimetrazine tartrate may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.
Phendimetrazine tartrate is not recommended for patients who used any anorectic agents within the prior year.
Caution is to be exercised in prescribing phendimetrazine for patients with even mild hypertension.
Insulin requirements in diabetes mellitus may be altered in association with the use of phendimetrazine tartrate and the concomitant dietary regimen.
Phendimetrazine tartrate may decrease the hypotensive effect of guanethidine.
The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.
Only yellow tablet contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons.
Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
Drug Interactions:
Efficacy of phendimetrazine tartrate with other anorectic agents has not been studied and the combined use may have the potential for serious cardiac problems.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Studies with Phendimetrazine Tartrate have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.
Pregnancy:
Pregnancy Category C:
Animal reproduction studies have not been conducted with phendimetrazine tartrate.
It is also not known whether phendimetrazine tartrate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
Usage in Pregnancy: Safe use in pregnancy has not been established.
Until more information is available, phendimetrazine tartrate should not be taken by women who are or may become pregnant unless, in the opinion of the physician, the potential benefits outweigh the possible hazards.
Nursing Mothers: It is not known whether this drug is excreted in human milk.
Because many drugs are excreted in human milk, phendimetrazine tartrate should not be taken by women who are nursing unless, in the opinion of the physician, the potential benefits outweigh the possible hazards.
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Quoted from the official label, section “Warnings”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

Acute overdosage with phendimetrazine tartrate may manifest itself by the following signs and symptoms:
unusual restlessness, confusion, belligerence, hallucinations, and panic states.
Fatigue and depression usually follow the central stimulation.
Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse.
Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps.
Poisoning may result in convulsions, coma, and death.
The management of overdosage is largely symptomatic.
It includes sedation with a barbiturate.
If hypertension is marked, the use of a nitrate or rapid-acting alpha receptor-blocking agent should be considered.
Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations for its use.

Quoted from the official label, section “Overdosage”.

Misuse and dependence

Controlled Substance:
Phendimetrazine tartrate tablets are a Schedule lll controlled substance.
Dependence:
Phendimetrazine tartrate is related chemically and pharmacologically to the amphetamines.
Amphetamines and related stimulant drugs have been extensively abused, and the possibility of abuse of phendimetrazine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program.
Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction.
There are reports of patients who have increased the dosage to many times that recommended.
Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG.
Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes.
The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia.

Quoted from the official label, section “Drug Abuse and Dependence”.

Side effects

Cardiovascular: Palpitations, tachycardia, elevated blood pressure, ischemic events.
Valvular heart disease associated with the use of some anorectic agents such as fenfluramine and dexfenfluramine, both independently and especially when used in combination with other anorectic drugs, have been reported.
However, no case of this valvulopathy has been reported when phendimetrazine tartrate has been used alone.
Central Nervous System:
Overstimulation, restlessness, insomnia, agitation, flushing, tremor, sweating, dizziness, headache, psychotic state, blurring of vision.
Gastrointestinal: Dryness of the mouth, nausea, diarrhea, constipation, stomach pain.
Genitourinary: Urinary frequency, dysuria, changes in libido.

Quoted from the official label, section “Adverse Reactions”.

What it looks like and how it is packed

Phendimetrazine Tartrate Tablets, USP 35 mg are available as White, round, biconvex tablets debossed “K” above bisect “45” on one side and plain on the other side.
Bottles of 30 NDC 10702-045-03 Bottles of 100 NDC 10702-045-01 Bottles of 1000 NDC 10702-045-10 Yellow, round, biconvex tablets debossed “K” above bisect “77” on one side and plain on the other side.
Bottles of 30 NDC 10702-077-03 Bottles of 100 NDC 10702-077-01 Bottles of 1000 NDC 10702-077-10 Blue, round, biconvex tablets debossed “K” above bisect “78” on one side and plain on the other side.
Bottles of 30 NDC 10702-078-03 Bottles of 100 NDC 10702-078-01 Bottles of 1000 NDC 10702-078-10

Quoted from the official label, section “How Supplied”.

What is in it

Phendimetrazine tartrate, as the dextro isomer, has the chemical name of (2S,3S)-3,4-Dimethyl-2-phenylmorpholine L-(+)- tartrate (1:1).
The structural formula is:
Phendimetrazine tartrate is a white, odorless crystalline powder.
It is freely soluble in water; sparingly soluble in warm alcohol, insoluble in chloroform, acetone, ether and benzene.
Each white tablet, for oral administration, contains 35 mg of phendimetrazine tartrate.
In addition, the following inactive ingredients are present:
Colloidal Silicon Dioxide, Lactose Monohydrate, Microcrystalline Cellulose 102, Sodium Starch Glycolate and Stearic Acid.
The yellow tablet also contains FD&C Yellow # 5 Aluminum Lake (15-17%).
The blue tablet also contains FD&C Blue # 1 Aluminum Lake (11-13%). chemical structure

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

LactoseLactose MonohydrateMilk sugar: matters with lactose intolerance or a milk allergy.

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (11)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Showing 11 of 11

Details

Made by	Calvin Scott & Co., Inc.
Active substance	Phendimetrazine Tartrate
Strength	35 mg
Form	Tablet
Route	Oral
Packs	14 TABLET in 1 BOTTLE, PLASTIC · 180 TABLET in 1 BOTTLE, PLASTIC
NDC	17224-800

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

12 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Tablet11 products
- 35 mg11
  35 mg · 11 companies
  - A-S Medication Solutions
  - Bryant Ranch Prepack
  - Calvin Scott & Co., Inc. · this page
  - Elite Laboratories, Inc
  - KVK-TECH, INC
  - NuCare Pharmaceuticals, Inc
  - NuCare Pharmaceuticals, Inc.
  - NuCare Pharmaceuticals,Inc.
  +3 more
Capsule, Extended Release1 products
- 105 mg

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

See every product with Phendimetrazine Tartrate